Last updated: 2026-10-19 23:40:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Obsidian Therapeutics, Inc. (OBX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.94, with a market capitalization of $727.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.56 to $49.97. This page covers its latest market performance, valuation, price trends and company information.
$727.07M | |
$11.75 | |
$49.97 | |
$11.56 | |
$11.77 | |
83.69K | |
408.18K | |
-- | |
$49.97 | |
$11.56 | |
-- | |
-- |
Obsidian Therapeutics, Inc. (OBX) is trading at $11.94 in after-hours trading as of 2026-10-19 21:53:00, up 1.40% ($0.17) from the regular-session close of $11.77.
After-hours trading shows how investors are pricing OBX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Obsidian Therapeutics, Inc. (OBX) moved from $12.24 to $11.94, representing a decline of 2.49% ($0.30).
The stock traded between $11.56 and $13.95 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 383.29 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.0%
OBX is currently trading at $11.94, placing it 1.0% of the way from its 52-week low of $11.56 to its 52-week high of $49.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Obsidian Therapeutics, Inc. (OBX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.